STN- Structure Search 2/1/07

10/517,677

=> d ibib abs hitstr 1-35

L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1226057 CAPLUS
DOCUMENT NUMBER: 146:20332
TITLE: Compositions and methods for treatment of eye disorders
INVENTOR(S): Gadek, Thomas; Burnier, John
PATENT ASSIGNEE(S): Sarcode, USA
SOURCE: PCT Int. Appl., 140pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2006125119 | A1 | 20061123 | WO 2006-US19327 | | 20060517 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| US 2006281739 | A1 | 20061214 | US 2006-436906 | | 20060517 |
| PRIORITY APPLN. INFO.: | | | US 2005-681684P | P | 20050517 |
| | | | US 2005-681722P | P | 20050517 |
| | | | US 2005-681723P | P | 20050517 |
| | | | US 2005-681772P | P | 20050517 |

OTHER SOURCE(S): MARPAT 146:20332

AB The present invention provides compds. and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compds. which are LFA-1 antagonists.

IT 915397-65-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treatment of eye disorders)

RN 915397-65-8 CAPLUS

CN L-Phenylalanine, N-[[1,3-dichloro-6-[[(2-furanylmethyl)amino]carbonyl]-2-naphthalenyl]carbonyl]-3-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:632681 CAPLUS
DOCUMENT NUMBER: 145:262434
TITLE: Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations
AUTHOR(S): Kirchmair, Johannes; Wolber, Gerhard; Laggner, Christian; Langer, Thierry
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, A-6020, Austria
SOURCE: Journal of Chemical Information and Modeling (2006), 46(4), 1848-1861
CODEN: JCISD8; ISSN: 1549-9596
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In continuation of our studies to evaluate the ability of various conformer generators to produce bioactive conformations, the authors present the extension of our work on the anal. of Catalyst's conformational subsampling algorithm in a comparative evaluation with OpenEye's currently updated tool Omega 2.0. Our study is based on an enhanced test set of 778 drug mols. and pharmacol. relevant compds. extracted from the Protein Data Bank (PDB). The authors elaborated protocols for two common conformer generation use cases and applied them to both programs: (i) high-throughput settings for processing large databases and (ii) high-quality settings for binding site exploration or lead structure refinement. While Catalyst is faster in the first case, Omega 2.0 better reproduces the bound ligand conformations from the PDB in less time for the latter case.

IT 219316-40-2
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparative performance of conformational model generators Omega and Catalyst in retrieval of protein-bound ligand conformations)

RN 219316-40-2 CAPLUS
CN Pentanoic acid, 5-amino-4-[[[6-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:630866 CAPLUS
DOCUMENT NUMBER: 145:103442
TITLE: Non-secosteroidal phenylnaphthalene compounds as vitamin d receptor modulators and their preparation, pharmaceutical compositions and use in treatment of diseases
INVENTOR(S): Gossett, Lynn Stacy; Lopez, Jose Eduardo; Warshawsky, Alan M.; Yee, Ying Kwong
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006069153 | A2 | 20060629 | WO 2005-US46360 | 20051219 |
| WO 2006069153 | A3 | 20060914 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-637930P P 20041221
OTHER SOURCE(S): MARPAT 145:103442
GI




I




II

AB The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compds. of formula I and their preparation, pharmaceutical compns., and methods of use. Compds. of formula I wherein, R and R' are independently C1-5 (halo)alkyl or RR' together form a (un)substituted (un)saturated C3-8 cycloalkyl; RP3 and RN are independently H, halo, C1-5 (halo)alkyl, S-C1-5 (halo)alkyl, O-C1-5 (halo)alkyl, CN, NO2, acetyl, C2-5 alkenyl, or C3-5 cycloalkenyl; L1-L3 are independently (CH2)m-C(OH), (CH2)m-O, (CH2)m-S, (CH2)m-SO, (CH2)m-SO2, (CH2)m-NH and derivs., (un)substituted alkyl, etc.; Z1 is branched C3-5 alkyl, C3-10 hydroxy(cyclo)alkyl, C3-10 hydroxyalkenyl, C3-10 hydroxyalkynyl, C4-10 hydroxycycloalkenyl, or oxocycloalkyl; Z3 is C1-5 (hydroxy)alkyl, C2-5 alkenyl, C3-5 cycloalkyl, C3-5 cycloalkenyl, C1-5 haloalkyl, C1-5 (hydroxy)alkylaryl, etc.; m is 0 to 5; and their pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereoisomers, and mixts. or diastereoisomers are claimed. Example compound II was prepared by amidation of 6-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]naphthalene-2-carboxylic acid with sarcosine Et ester hydrochloride followed by hydrolysis of the resulting amido ester to give compound II. All the invention compds. were evaluated for their vitamin D receptor affinity. From the assay, it was was determined that compound II exhibited IC50 values of 24 nM against keranocyte proliferation and 5 nM against IL-10.

IT 895520-35-1P 895520-52-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of non-secosteroidal, phenylnaphthalene compds. as vitamin D receptor modulators useful in treatment of diseases)

RN 895520-35-1 CAPLUS

CN Glycine, N-[[6-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 895520-52-2 CAPLUS
CN Glycine, N-[[6-[1-ethyl-1-[4-(1-ethyl-2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:365240 CAPLUS
DOCUMENT NUMBER: 144:412505
TITLE: Benzimidazole or indole amides as inhibitors of pin1 and their preparation, pharmaceutical compositions, and use for treatment of diseases associated with abnormal cell growth
INVENTOR(S): Do, Quyen-Quyen Thuy; Guo, Chuangxing; Humphries, Paul Stuart; Marakovits, Joseph Timothy; Dong, Liming; Hou, Xinjun; Johnson, Mary Catherine
PATENT ASSIGNEE(S): Pfizer, Inc., USA
SOURCE: PCT Int. Appl., 396 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006040646 | A1 | 20060420 | WO 2005-IB3019 | 20051003 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2004-619211P P 20041014
OTHER SOURCE(S): MARPAT 144:412505
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of the formula I and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compds. of formula I and to pharmaceutical compns. for treating such disorders that contain the compds. of formula I. The invention also relates to methods of preparing the compds. of formula I. Compds. of formula I wherein Q, Q1, Q2, and Q3 are independently N, CH2 or CH, where not more than two of the Qs are N; T is CH or N; T1 is O, NH or NMe; X is NH, O, CH=, or NR'; R' is (un)substiuted alkyl; Y is CO, CH2, or CONH and derivs.; Z is H or (un)substiuted alkyl; XY and X can form a heterocyclic ring or X and Y can form a heterocyclic ring; R and V are independently H, halo, alkyl, halogenated alkyl, alkoxy, OH, NH2, CN; R1 is (un)substituted (hetero)aryl, (un)substituted aryloxy, (un)substituted arylsulfanyl, (un)substituted arylvinyl or (un)substituted arylalkyl(amino), etc.; R3 is CO2H, tetrazole, CO2CHR4OCOR4 or CONH2 and derivs.; R4 is H or alkyl; and their pharmaceutically acceptable salts and solvates are claimed in this invention. Example compound II was prepared by substitution of compound II with benzoxazole-2-thiol followed by hydrolysis at the ester. Addnl. 1400 example compds. were prepared in this invention. All invention compds. were evaluated for their pin1 inhibitory activity. Example compound II showed 10% inhibition at 1 μM and 73% inhibition at 10 μM concentration Most of the invention compds. showed good inhibitory activity at 10 μM concentration

IT 884033-52-7P 884035-28-3P 884035-30-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazole or indole amides as inhibitors of pin1 useful for treatment of diseases associated with abnormal cell growth)

RN 884033-52-7 CAPLUS
CN 1H-Benzimidazole-2-propanoic acid, α-[[(6-methoxy-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 884035-28-3 CAPLUS
CN 1H-Indole-2-propanoic acid, 5-chloro-α-[[[6-[2-(dimethylamino)ethoxy]-2-naphthalenyl]carbonyl]amino]-, (αR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 884035-27-2
CMF C26 H26 Cl N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 884035-30-7 CAPLUS
CN 1H-Indole-2-propanoic acid, α-[[[6-[2-(dimethylamino)ethoxy]-2-naphthalenyl]carbonyl]amino]-6-fluoro-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1004736 CAPLUS
DOCUMENT NUMBER: 143:306307
TITLE: Preparation of pyrazolecarboxamides as novel insecticides
INVENTOR(S): Hughes, Dave; Peace, James Edward; Riley, Suzanna; Russel, Sally; Swanborough, Joe; Hall, Roger Graham; Jeanguenat, Andre; Loiseleur, Olivier; Renold, Peter; Trah, Stephan; Wenger, Jean
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.; Syngenta Limited
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | | |
|---|---|---|---|---|---|
| WO 2005085234 | | A2 | 20050915 | WO 2005-EP2204 | 20050302 |
| WO 2005085234 | | A3 | 20060126 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005219545 | | A1 | 20050915 | AU 2005-219545 | 20050302 |
| CA 2556387 | | A1 | 20050915 | CA 2005-2556387 | 20050302 |
| EP 1737844 | | A2 | 20070103 | EP 2005-715671 | 20050302 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| GB 2004-4801 | A | 20040303 |
| GB 2004-11078 | A | 20040518 |
| GB 2004-25453 | A | 20041118 |
| WO 2005-EP2204 | W | 20050302 |

OTHER SOURCE(S): MARPAT 143:306307

GI




AB The title compds. I [Z1, Z2 = O, S; R1 = (un)substituted aryl or heteroaryl; R2-R4 = H or an organic substituent; or NR3R4 = (un)substituted ring; R5 = H, (un)substituted alkyl; or forms, taken together with R8 or with a monovalent substituent attached to that atom of R6, via which atom R6 is directly connected with the carbon atom, which carries R5, one addnl. bond; R6 and R7, taken together, form, together with the two carbon atoms, to which atoms they are attached, a bicyclic ring system, which ring system is carbocyclic or heterocyclic, which ring system is substituted by the four substituents NR2C(:Z1)R1, C(:Z2)NR3R4, R5 and R8, and which ring system is optionally further substituted; and R8 = H, (un)substituted alkyl; or forms, taken together with R5 or with a monovalent substituent attached to that atom of R7, via which atom R7 is directly connected with the carbon atom, which carries R8, one addnl. bond], useful for controlling insects or representatives of the order Acarina, were prepared E.g., a multi-step synthesis of II, starting from 2-amino-3-carboxynaphthalene, was given. The compds. I were tested against various pests (specific data were given for representative compds. I).

IT 864677-29-2P 864677-30-5P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolecarboxamides as novel insecticides)

RN 864677-29-2 CAPLUS
CN Alanine, N-[[7-bromo-4-chloro-3-[[[1-(3-chloro-2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]-2-naphthalenyl]carbonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 864677-30-5 CAPLUS
CN Glycine, N-[[7-bromo-4-chloro-3-[[[1-(3-chloro-2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:595110 CAPLUS
DOCUMENT NUMBER: 143:248596
TITLE: Regio- and stereocontrolled total synthesis of benanomicin B
AUTHOR(S): Ohmori, Ken; Tamiya, Minoru; Kitamura, Mitsuru; Kato, Hirohisa; Oorui, Mami; Suzuki, Keisuke
CORPORATE SOURCE: Department of Chemistry, SORST-JST Agency, Tokyo Institute of Technology, Tokyo, 152-8551, Japan
SOURCE: Angewandte Chemie, International Edition (2005), 44(25), 3871-3874
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:248596

AB Fully controlled total synthesis of benanomicin B was achieved by exploiting two key steps: a stereocontrolled ring-opening of a lactone and

a semipinacol cyclization of an acetal-aldehyde derivative discriminating the two hydroxy groups of the pseudo-C2-sym. 1,2-diol moiety.

IT 863423-77-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regio- and stereo-controlled total synthesis of benanomicin B via ring-opening of lactone and semipinacol cyclization of acetalaldehyde deriv)

RN 863423-77-2 CAPLUS

CN Benzoic acid, 3-[3-[[[(1S)-1-carboxy-2-methylpropyl]amino]carbonyl]-6-chloro-1-hydroxy-5,8-dimethoxy-2-naphthalenyl]-2-hydroxy-6-methyl-4-[[[tris(1-methylethyl)silyl]oxy]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventor?

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:989723 CAPLUS
DOCUMENT NUMBER: 140:28042
TITLE: Preparation of N-naphthoylphenylalanines as prostaglandin I2 antagonists
INVENTOR(S): Shimazaki, Makato; Sakurai, Osamu; Urbahns, Klaus; Yamamoto, Noriyuki; Yoshikawa, Satoru; Umeda, Masaomi; Tajimi, Masaomi
PATENT ASSIGNEE(S): Bayer Ag, Germany
SOURCE: Brit. UK Pat. Appl., 26 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| GB 2389580 | A | 20031217 | GB 2002-13488 | 20020612 |
| CA 2489286 | A1 | 20031224 | CA 2003-2489286 | 20030530 |
| WO 2003106402 | A1 | 20031224 | WO 2003-EP5705 | 20030530 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| AU 2003238180 | A1 | 20031231 | AU 2003-238180 | 20030530 |
| EP 1515941 | A1 | 20050323 | EP 2003-735507 | 20030530 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2005529180 | T | 20050929 | JP 2004-513236 | 20030530 |
| US 2006166989 | A1 | 20060727 | US 2005-517677 | 20050711 |
| PRIORITY APPLN. INFO.: | | | GB 2002-13488 A | 20020612 |
| | | | WO 2003-EP5705 W | 20030530 |

OTHER SOURCE(S): MARPAT 140:28042

GI



I

AB Title compds. [I; m, n = 0-2; R1 = OR11, SR11, SOR11 SO2R11, NR12R13, CHR14R15; R11 = alkenyl, alkynyl alkyl optionally substituted by aryl or heteroaryl; R12, R13 H , R11; R12R13N = 5-7 membered saturated heterocyclyl interrupted by O or NH; R14, R15 H , alkenyl optionally substituted by aryl or heteroaryl, alkynyl optionally substituted by aryl or heteroaryl, alkyl optionally substituted by aryl or heteroaryl, alkoxy optionally substituted by aryl or heteroaryl; R14R15CH = cycloalkyl optionally interrupted by NH, or O, or R14R15CH = Ph optionally substituted by OH, halo or alkyl; R2 = H, cyano, alkoxy, alkenyl, alkynyl, cycloalkyl, alkyl optionally substituted by amino, alkylamino, Ph], were prepared for treatment of pain, inflammation, urol. disorders, hypotension, hemophilia, and hemorrhage (no data). Thus, 6-hydroxy-2-naphthoic acid, DL-phenylalanine Me ester, 1-hydroxybenzotriazole, Et3N, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were stirred overnight in DMF to give 85% N-(6-hydroxy-2-naphthoyl)phenylalanine Me ester. This was benzylated (76%) followed by saponification with LiOH in H2O/MeOH to give 82% N-(6-benzyloxy-2-naphthoyl)phenylalanine.

IT 634206-86-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-naphthoylphenylalanines as prostaglandin I2 antagonists)

RN 634206-86-3 CAPLUS

CN Phenylalanine, N-[[6-(phenylmethoxy)-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:907753 CAPLUS
DOCUMENT NUMBER: 140:314391
TITLE: Structure-based prediction of free energy changes of binding of PTP1B inhibitors
AUTHOR(S): Wang, Jing; Ling Chan, Shek; Ramnarayan, Kal
CORPORATE SOURCE: Structural Bioinformatics Inc., San Diego, CA, 92127, USA
SOURCE: Journal of Computer-Aided Molecular Design (2003), 17(8), 495-513
CODEN: JCADEQ; ISSN: 0920-654X
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The goals were (1) to understand the driving forces in the binding of small mol. inhibitors to the active site of PTP1B and (2) to develop a mol. mechanics-based empirical free energy function for compound potency prediction. A set of compds. with known activities was docked onto the active site. The related energy components and mol. surface areas were calculated The bridging water mols. were identified and their contributions were considered. Linear relationships were explored between the above terms and the binding free energies of compds. derived based on exptl. inhibition consts. We found that minimally three terms are required to give rise to a good correlation (0.86) with predictive power in five-group cross-validation test (q2 = 0.70). The dominant terms are the electrostatic energy and non-electrostatic energy stemming from the intra- and intermol. interactions of solutes and from those of bridging water mols. in complexes.

IT 679401-36-6 679401-37-7
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(structure-based prediction of free energy changes of binding of PTP1B inhibitors)

RN 679401-36-6 CAPLUS
CN L-Glutamic acid, N-[[6-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 679401-37-7 CAPLUS
CN D-Glutamic acid, N-[[6-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:133577 CAPLUS
DOCUMENT NUMBER: 138:183523
TITLE: Reagent for determining hydrogen peroxide in clinical assay
INVENTOR(S): Okabe, Kazuaki; Kadota, Akira; Aoki, Kozo; Takahashi, Kazunobu; Sakurada, Masami; Nakamura, Kouki
PATENT ASSIGNEE(S): Kyowa Medex Co., Ltd., Japan; Fuji Photo Film Co., Ltd.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003014725 | A1 | 20030220 | WO 2002-JP7905 | 20020802 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1424554 | A1 | 20040602 | EP 2002-755787 | 20020802 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| US 2005130251 | A1 | 20050616 | US 2003-485698 | 20020802 |
| PRIORITY APPLN. INFO.: | | | JP 2001-234597 A | 20010802 |
| | | | WO 2002-JP7905 W | 20020802 |

OTHER SOURCE(S): MARPAT 138:183523
GI



II



III

AB A reagent for colorimetrically determining hydrogen peroxide in a clin. assay is provided, which comprises: (A) a compound represented by the general formula (I): R1-NH-R2 (I) <R1 represents carbamoyl group, etc.; and R2 represents arylamino group, heteroarylamino group, or a substituent represented by the general formula II: (II) [R3 to R6 each represents X-Y-Ra {Ra represents hydrogen atom, alkyl group, etc.; X represents a single bond, oxygen, etc.; and Y represents a single bond, (C=O), etc.}, cyano group, halogen atom, etc.]>; (B) a compound represented by the general formula III: (III) [R9 represents a group eliminable through an oxidative color-developing coupling reaction with the compound (I); and R7, R8, and R10 to R13 each has the same meaning as R3], etc.; and (C) an peroxidn.-active substance (e.g., peroxidase).

IT 497861-06-0
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(reagent for determining hydrogen peroxide in clin. assay)

RN 497861-06-0 CAPLUS

CN Alanine, N-[[1-hydroxy-5-[[(2-methylpropoxy)carbonyl]amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:117825 CAPLUS

DOCUMENT NUMBER: 138:170259

TITLE: Preparation of dipyridodiazepinones as reverse transcriptase inhibitors

INVENTOR(S): Ogilvie, William W.; Deziel, Robert; O'Meara, Jeffrey; Simoneau, Bruno

PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.

SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003011862 | A1 | 20030213 | WO 2002-CA1161 | 20020726 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003171363 | A1 | 20030911 | US 2002-205094 | 20020725 |
| US 6673791 | B2 | 20040106 | | |
| CA 2450868 | A1 | 20030213 | CA 2002-2450868 | 20020726 |
| EP 1414820 | A1 | 20040506 | EP 2002-750729 | 20020726 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2004537568 | T | 20041216 | JP 2003-517054 | 20020726 |
| PRIORITY APPLN. INFO.: | | | US 2001-308710P P | 20010730 |
| | | | WO 2002-CA1161 W | 20020726 |

OTHER SOURCE(S): MARPAT 138:170259

GI




I

AB Title compds. [I; R2 = H, halo, NHNH2, alkyl, alkoxy, haloalkyl; R4 = H, Me; R5 = H, alkyl; R11 = alkyl, alkylcycloalkyl, cycloalkyl; Q = (substituted) naphthyl, fused phenylcycloalkyl, fused phenylheterocyclyl having 1-2 O, N, S], were prepared Thus, diisopropyl azodicarboxylate in THF was added dropwise to a mixture of 5,11-dihydro-11-ethyl-2-fluoro-5-methyl-8-(2-hydroxyethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, Ph3P, and 4-formyl-1-naphthol followed by stirring for 1 h to give 56% formylnaphthyl ether derivative, which was stirred with AgNO3 and NaOH in EtOH/THF to give 62% title compound I (Q = 4-carboxynaphthyl-1-yl; R2 = F; R4 = H; R5 = Me; R11 = Et) (II). II showed IC50<100 nM against wild type HIV-1 reverse transcriptase.

IT 497068-17-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dipyridodiazepinones as reverse transcriptase inhibitors)

RN 497068-17-4 CAPLUS

CN Alanine, N-[[6-[2-(11-ethyl-6,11-dihydro-5-methyl-6-oxo-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-8-yl)ethoxy]-2-naphthalenyl]carbonyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:888541 CAPLUS
DOCUMENT NUMBER: 137:369841
TITLE: Preparation of carboxylic acid derivatives as endothelial differentiation gene (EDG-1) receptor agonists and drugs containing the same as the active ingredient
INVENTOR(S): Seko, Takuya; Terakado, Masahiko; Kohno, Hiroshi; Takahashi, Shinya
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002092068 | A1 | 20021121 | WO 2002-JP4520 | 20020509 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2446593 | A1 | 20021121 | CA 2002-2446593 | 20020509 |
| EP 1391199 | A1 | 20040225 | EP 2002-769553 | 20020509 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2004224941 | A1 | 20041111 | US 2003-477106 | 20031110 |
| PRIORITY APPLN. INFO.: | | | JP 2001-140458 A | 20010510 |
| | | | WO 2002-JP4520 W | 20020509 |

OTHER SOURCE(S): MARPAT 137:369841
GI




I

AB [(Phenylalkanoyl)amino]benzoic acids and -benzamides represented by the following general formula [I; R1, R2 = C1-8 alkyl, C1-8 alkoxy, halo,NO2, CF3; the ring A = C5-7 monocyclic carbocyclic ring, 5 - to 7-membered monocyclic heterocyclic ring containing 1-2 N, 1 O, and/or 1 S atoms; E = CH2, O, S, NH, C1-8 alkyl-N; R3, R4 = H, C1-8 alkyl; or R2 and R3 together represents CH2CH2 or CH:CH; G = N-(un)substituted CONH, NHCO, SO2NH, NHSO2, CH2NH, or NHCH2; Q = C1-4 alkylene, Q1 [wherein J1-J4 = CH, N; R5 = C1-8 alkyl, halo,NO2, cyano, CF3, CF3O, Ph, tetrazolyl, each (un)substituted HO, SH, NH2, CONH2, or CO2NH2, etc.; n = an integer of 0-4]; p = an integer of 0-5; q = an integer of 4-6; m = an integer of 0-4], prodrugs thereof, or salts thereof and drugs containing the same as the active ingredient are disclosed. Because of having an EDG-1 agonism, the compds. of the general formula I are useful in preventing and/or treating arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease, peripheral arterial disease of diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, brain infarction, myocardial infarction, edematous diseases, arteriosclerosis, hemorrhoid, anal fissure, varicosity such as anal fistula, dissecting aneurysm, angina, DIC, pleuritis, congestive heart failure, multiorgan failure, bedsore, ambustion (burn), ulcerative colitis, Crohn's disease, heart transplantation, kidney transplantation, skin transplantation, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, cirrhosis, chronic renal failure or glomerular sclerosis. For example, 2-carboxy-5-[3-[4-(5-phenylpentyloxy)phenyl]propanoylamino]benzoi c acid in vitro showed the agonism activity with EC50 of 14 nM for increasing cellular Ca2+ concentration in Chinese hamster overly (CHO) cell overexpressing human EDG-1 gene. A tablet and an ampule formulation containing 2-chloro-5-[3-[4-(5-phenylpentyloxy)phenyl]propanoylamino]benzoic acid were described.

IT 475597-70-7P 475597-71-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(phenylalkanoyl)amino]benzoic acids and -benzamides derivs. as endothelial differentiation gene (EDG-1) receptor agonists for treatment or prevention of diseases)

RN 475597-70-7 CAPLUS
CN Glycine, N-[[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 475597-71-8 CAPLUS
CN β-Alanine, N-[[6-[(5-phenylpentyl)oxy]-2-naphthalenyl]carbonyl]-

(9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:256223 CAPLUS
DOCUMENT NUMBER: 136:295089
TITLE: Preparation of amino acid aromatic derivatives with HIV integrase inhibitory properties
INVENTOR(S): N'zemba, Blaise Magloire; Sauve, Gilles; Sevigny, Guy; Yelle, Jocelyn
PATENT ASSIGNEE(S): Pharmacor, Inc., Can.
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002026697 | A2 | 20020404 | WO 2001-CA1367 | 20010925 |
| WO 2002026697 | A3 | 20020516 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2321348 | A1 | 20020327 | CA 2000-2321348 | 20000927 |
| AU 2001095310 | A5 | 20020408 | AU 2001-95310 | 20010925 |
| US 6528655 | B1 | 20030304 | US 2001-963329 | 20010926 |
| PRIORITY APPLN. INFO.: | | | CA 2000-2321348 A | 20000927 |
| | | | WO 2001-CA1367 W | 20010925 |

OTHER SOURCE(S): MARPAT 136:295089

AB Amino acid derivs. R1CO-A-CONHR2 [A = NR3CR4R5, where R3, R4 = H or Me; R5 = H, alkyl, carboxyalkyl, benzyl, MeSCH2CH2, 1-indolylmethyl, 3,4-(HO)2C6H2CH2, etc.; R3R4 may be trimethylene, which may be substituted; R1, R2 are certain rings (Ph, 3-pyridyl, 2-quinolyl, 2-thienyl, etc.), which may be substituted and attached to alkyl; R2 may also be aroylamino] were prepared as inhibitors of HIV integrase. Thus, N-[Nα-(3,4-dihydroxybenzoyl)-Nτ-trityl-L-histidinyl]dopamine was prepared by coupling of Nα-(9-fluorenylmethoxycarbonyl)-Nτ-trityl-L-histidine with dopamine hydrochloride, deprotection, and acylation with 3,4-dihydroxybenzoic acid and showed anti-integrase activity IC50 = 65 nM.

IT 406728-08-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid aromatic derivs. with HIV integrase inhibitory

properties)
RN 406728-08-3 CAPLUS
CN L-Lysine, N2,N6-bis[(3,5-dihydroxy-2-naphthalenyl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:834777 CAPLUS
DOCUMENT NUMBER: 136:173460
TITLE: Aromatic anion recognition by a self-assembled receptor in water
AUTHOR(S): Kim, Hae-Jo; Lim, Choon Woo; Hong, Jong-In
CORPORATE SOURCE: School of Chemistry and Molecular Engineering, Seoul National University, Seoul, 151-747, S. Korea
SOURCE: Materials Science & Engineering, C: Biomimetic and Supramolecular Systems (2001), C18(1-2), 265-269
CODEN: MSCEEE; ISSN: 0928-4931
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Self-assembly of (1R,2R)-diaminocyclohexane derived bis(4-pyridyl)-substituted bidentate ligand L* by Pd(II) ion complexation leads to a water-soluble chiral receptor 1. The new chiral receptor turns out to bind naphthalene derivs. bearing tethered carboxylate groups due to the entropically driven host-guest complexation process.
IT 396665-07-9 396665-19-3 396665-23-9
396665-27-3 396665-29-5 396665-39-7
396665-41-1 396665-43-3 396665-45-5
396665-53-5 396665-67-1
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(aromatic anion host-guest complexation by self-assembled palladium(II)-1R,2R)-bis(4-pyridyl)diaminocyclohexane in water)
RN 396665-07-9 CAPLUS
CN Palladium(4+), bis[μ-[N,N'-(1R,2R)-1,2-cyclohexanediylbis[4-pyridinecarboxamide-κN1]]]bis(1,2-ethanediamine-κN,κN')di-, sodium nitrate salt with 6-[[(1-carboxyethyl)amino]carbonyl]-2-naphthalenecarboxylic acid (1:2:4:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396665-06-8
CMF C15 H11 N O5

CM 3

CRN 14797-55-8
CMF N O3



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:540902 CAPLUS
DOCUMENT NUMBER: 135:282678
TITLE: Utilization of a peptide lead for the discovery of a novel PTP1B-binding motif
AUTHOR(S): Gao, Yang; Voigt, Johannes; Zhao, He; Pais, Godwin C. G.; Zhang, Xuechun; Wu, Li; Zhang, Zhong-Yin; Burke, Terrence R., Jr.
CORPORATE SOURCE: Laboratory of Medicinal Chemistry Center for Cancer Research, National Cancer Institute, NCI-Frederick, Frederick, MD, 21702, USA
SOURCE: Journal of Medicinal Chemistry (2001), 44(18), 2869-2878
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:282678

AB Examination of the PTP1B inhibitory potency of an extensive series of phosphotyrosyl (pTyr) mimetics (Xxx) expressed in the EGFr-derived hexapeptide platform Ac-Asp-Ala-Asp-Xxx-Leu-amide previously led to the finding of high inhibitory potency when Xxx = 4-(phosphonodifluoromethyl)phenylalanyl (F2Pmp) (Ki = 0.2 μM) and when Xxx = 3-carboxy-4-carboxymethyloxyphenylalanyl (Ki = 3.6 μM). In the first instance, further work led from the F2Pmp-containing peptide to monomeric inhibitor, 6-(phosphonodifluoromethyl)-2-naphthoic acid (Ki = 22 μM), and to the pseudo-dipeptide mimetic, N-[6-(phosphonodifluoromethyl)-2-naphthoyl]-glutamic acid (Ki = 12 μM). In the current study, a similar approach was applied to the 3-carboxy-4-carboxymethyloxyphenylalanyl-containing peptide, which led to the preparation of monomeric 5-carboxy-6-carboxymethyloxy-2-naphthoic acid (Ki = 900 μM). However, contrary to expectations based on the aforementioned F2Pmp work, incorporation of this putative pTyr mimetic into the pseudo-dipeptide, N-[5-carboxy-6-carboxymethyloxy-2-naphthoyl]-glutamic acid, resulted in a substantial loss of binding affinity. A reevaluation of binding orientation for 5-carboxy-6-carboxymethyloxy-2-naphthoic acid was therefore undertaken, which indicated a 180° reversal of the binding orientation within the PTP1B catalytic site. In the new orientation, the naphthyl 2-carboxyl group, and not the o-carboxy carboxymethyloxy groups, mimics a phosphoryl group. Indeed, when 5-carboxy-2-naphthoic acid itself was examined at neutral pH for inhibitory potency, it was found to have Ki = 31 ± 7 μM, which is lower than parent 5-carboxy-6-carboxymethyloxy-2-naphthoic acid. In this fashion,

5-carboxy-2-naphthoic acid (or more appropriately, 6-carboxy-1-naphthoic acid) has been identified as a novel PTP1B binding motif.

IT 364371-95-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(discovery of novel PTP1B-binding motif)

RN 364371-95-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 2-(carboxymethoxy)-6-[[[(1S)-1-(aminocarbonyl)-3-carboxypropyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219316-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(discovery of novel PTP1B-binding motif)

RN 219316-40-2 CAPLUS

CN Pentanoic acid, 5-amino-4-[[[6-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:883029 CAPLUS

DOCUMENT NUMBER: 134:360982

TITLE: Structural requirements to obtain potent CAAX mimic P21-ras farnesyltransferase inhibitors

AUTHOR(S): Laoui, Abdelazize

CORPORATE SOURCE: Medicinal Chemistry Department, Molecular Modelling Rhone-Poulenc Rorer S. A. - Centre de Recherches de Vitry-Alfortville, Vitry-sur-Seine, 94403, Fr.

SOURCE: Molecular Modeling and Prediction of Bioactivity, [Proceedings of the European Symposium on Quantitative Structure-Activity Relationships: Molecular Modeling and Prediction of Bioactivity], 12th, Copenhagen,

Denmark, Aug. 23-28, 1998 (2000), Meeting Date 1998, 408-409. Editor(s): Gundertofte, Klaus; Jorgensen, Flemming Steen. Kluwer Academic/Plenum Publishers: New York, N. Y.
CODEN: 69ASO3
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Farnesyltransferase (FTase) farnesylates p21ras on the Cys residue of the C-terminal consensus sequence referred to as a CAAX box (C = cysteine, A = an aliphatic amino acid; X = any amino acid). This modification is required for membrane association and function of both normal and cell transforming ras activity. Computer modeling studies of corporate and competitor FTase inhibitors which have led to the identification of the structural requirements necessary to obtain potent inhibitors, are presented. Also, the strategy adopted to replace the oxidizable thiol function of inhouse inhibitors with alternative zinc chelating groups, is reported. The peptidomimetic strategy has allowed the development of a series of inhibitors derived from a known peptidic inhibitor.

IT 340720-03-8 340720-06-1 340720-07-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(structural requirements to obtain potent CAAX mimic P21-ras farnesyltransferase inhibitors)

RN 340720-03-8 CAPLUS
CN L-Methionine, L-cysteinyl-6-amino-2-naphthalenecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 340720-06-1 CAPLUS
CN L-Methionine, L-cysteinyl-5-amino-2-naphthalenecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 340720-07-2 CAPLUS
CN L-Methionine, L-cysteinyl-8-amino-2-naphthalenecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:53681 CAPLUS
DOCUMENT NUMBER: 132:108302
TITLE: Preparation of CS-1 peptidomimetics and their compositions
INVENTOR(S): Arrhenius, Thomas S.; Elices, Mariano J.; Gaeta, Federico C. A.; He, Ya-Bo; Huyghe, Bernard G.; Chen, Paul G.
PATENT ASSIGNEE(S): Cytel Corporation, USA
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2000002903 | A1 | 20000120 | WO 1998-US26605 | | 19981215 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 9919153 | A | 20000201 | AU 1999-19153 | | 19981215 |
| PRIORITY APPLN. INFO.: | | | US 1998-113689 | A | 19980710 |
| | | | WO 1998-US26605 | W | 19981215 |

OTHER SOURCE(S): MARPAT 132:108302

AB Peptidomimetics R1CONR2CHR3CONR4CH(CONR5R6)CH2CO2H [R1 = alkyl, aminoalkyl, or a ring structure which may form at R1, between R1 and R2 or between R1 and R4; R2 = H, alkyl, phenylalkyl or R2 and R1 form the R1 ring structure group; R3 = alkyl, alkyl alc., thioalkyl, dialkyl thioether, or a ring structure; R4 = H or R4 and R1 form the R1 ring structure; R5 = H or R5 and R6 form a ring structure; R6 = benzyl, an optionally substituted 5-, 6-, or 7-membered heterocyclic ring containing 1 or 2 nitrogen atoms, a pyridobenzazepine moiety, or a group CHR7CO-AR8R9 (A = N and R7, R8, R9 = alkyl, a ring structure, etc. or A = O and R7 = alkyl, a ring structure, etc., R8 = alkyl, and R9 is absent)] were prepared as inhibitors of the binding between the VLA-4 receptor and the fibronectin CS-1 domain. Thus, N-phenylacetyl-L-Leu-Asp-Phe-D-Pro-NH2 was prepared and assayed for binding inhibition potency (313 relative to a standard compound).

IT 209602-54-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of CS-1 peptidomimetics and their compns.)

RN 209602-54-0 CAPLUS

CN D-Prolinamide, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-L-α-aspartyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:505686 CAPLUS

DOCUMENT NUMBER: 131:139496

TITLE: Fibronectin CS-1 peptidomimetics for inhibiting binding of CS-1 to VLA-4 and for treating immunoinflammatory conditions

INVENTOR(S): Arrhenius, Thomas S.; Elices, Mariano J.; Gaeta, Federico C. A.

PATENT ASSIGNEE(S): Cytel Corporation, USA

SOURCE: U.S., 81 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5936065 | A | 19990810 | US 1995-462424 | 19950605 |
| CA 2177840 | A1 | 19950615 | CA 1994-2177840 | 19941205 |
| CN 1142832 | A | 19970212 | CN 1994-194969 | 19941205 |
| US 5688913 | A | 19971118 | US 1995-435286 | 19950505 |
| US 6117840 | A | 20000912 | US 1997-837154 | 19970414 |
| US 6103870 | A | 20000815 | US 1997-923026 | 19970903 |
| PRIORITY APPLN. INFO.: | | | US 1993-164101 | B2 19931206 |
| | | | US 1994-349024 | B2 19941202 |
| | | | US 1995-435286 | A1 19950505 |

OTHER SOURCE(S): MARPAT 131:139496

AB Peptidomimetic compds. are disclosed that inhibit the binding between the VLA-4 and the fibronectin CS-1 compound Pharmaceutical compns. containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.

IT 209602-54-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibronectin CS-1 peptidomimetics for inhibiting binding of CS-1 to VLA-4 and for treating immunoinflammatory conditions)

RN 209602-54-0 CAPLUS

CN D-Prolinamide, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-L-α-

aspartyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:325944 CAPLUS
DOCUMENT NUMBER: 130:338394
TITLE: Synthesis of phosphono-containing amino acid derivatives and peptides as signal transduction inhibitors
INVENTOR(S): Weigele, Manfred; Bohacek, Regine; Jacobsen, Virginia A.; Macek, Karina; Yang, Michael G.; Kawahata, Noriyuki H.; Sundaramoorthi, Rajeswari; Wang, Yihan; Takeuchi, Craig S.; Luke, George P.; Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Tomi
PATENT ASSIGNEE(S): Ariad Pharmaceuticals, Inc., USA; et al.
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9924442 | A1 | 19990520 | WO 1998-US24168 | 19981112 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2309792 | A1 | 19990520 | CA 1998-2309792 | 19981112 |
| AU 9914572 | A | 19990531 | AU 1999-14572 | 19981112 |
| EP 1030853 | A1 | 20000830 | EP 1998-958550 | 19981112 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| US 6576766 | B1 | 20030610 | US 2000-554230 | 20000817 |
| PRIORITY APPLN. INFO.: | | | US 1997-968490 A | 19971112 |
| | | | WO 1998-US24168 W | 19981112 |

OTHER SOURCE(S): MARPAT 130:338394
AB Title compds. Y-X-U-NR14(CR1R2)m-B [Y = (un)substituted PhMn, PhGMn, naphthyl-Mn, where G = O, S, NR [R = H, (un)substituted aliphatic, heteroaliph., aryl, heteroaryl, aryl aliph, or heteroaryl aliphatic moiety]; M = (un)substituted methylene, m = 0-2; X = (un)substituted methylene or imino; B = (un)substituted Ph or carbamoyl; U = CO, CS, M, SO, SO2; R1 = H or (un)substituted aliph, Mn-cycloaliph., Mn-aryl, Mn-heterocyclic; R2 = = H or (un)substituted aliphatic or R1 and R2 are covalently linked to form a

ring; R14 = H or R] were prepared for inhibiting intracellular signal transduction. Thus, [(4-{(S)-2-acetylamino-2-[(S)-1-(3-carbamoyl-4-cyclohexylmethoxyphenyl)ethylcarbamoyl]ethyl}phenyl)phosphonomethyl]phosphonic acid was synthesized by a multistep procedure starting from p-(Et2O3PCH2)-L-Phe-OH.

IT 224445-32-3P 224445-33-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of phosphono-containing amino acid derivs. and peptides as signal transduction inhibitors)

RN 224445-32-3 CAPLUS
CN Pentanoic acid, 4-[[[6-(carboxymethoxy)-5-formyl-2-naphthalenyl]carbonyl]amino]-5-[(3-cyclohexylpropyl)methylamino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 224445-33-4 CAPLUS
CN Pentanoic acid, 5-[(3-cyclohexylpropyl)methylamino]-4-[[[5-formyl-6-(phosphonooxy)-2-naphthalenyl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:260789 CAPLUS
DOCUMENT NUMBER: 130:344973
TITLE: Silver halide photographic material for color filter formation
INVENTOR(S): Mizukawa, Hiroki

10/517,677

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 48 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 11109123 | A | 19990423 | JP 1997-267112 | 19970930 |

PRIORITY APPLN. INFO.: JP 1997-267112 19970930
OTHER SOURCE(S): MARPAT 130:344973
GI




AB The material contains a red dye- or a magenta dye-releasing coupler having a formula Q1(TIME)nLmDY or a red or magenta colored coupler having a formula Q2N:NR1 [Q1, 2 = coupler residue I, II, or III; TIME = timing group that releases (TIME)n-1LmDY after eliminating Q1 or timing group that releases (TIME)n-2LmDY after being eliminated from TIME; R1 = aryl, heterocyclic; n, m = 0, 1, 2, 3; L = divalent group; DY = red or magenta dye residue; R2 = alkyl, cycloalkyl, alkenyl, aryl, heterocyclic, alkoxy, cycloalkyloxy, alkenyloxy, aryloxy, alkylamino, cycloalkylamino, alkenylamino, arylamino, heterocyclic amino; R3, 4 = substituent; p = 0-3 integer; R5, 7, 8 = H, substituent; q = 0-4 integer; M = CO, SO2; R6 = alkyl, cycloalkyl, aryl, heterocyclic, alkoxy, cycloalkyloxy, aryloxy, heterocyclicoxy, alkylamino, cycloalkylamino, arylamino, heterocyclic amino; Z1, 2 = N, CR9; R9 = H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclic]. The method involves exposing the material, color-developing, and desilverizing to obtain the filter having a blue, green, and red pixel pattern. The filter contains the coupler. The filter with light transmittance, excellent heat and light fastness, and thin film thickness is manufactured using the material.

IT 223734-73-4
RL: TEM (Technical or engineered material use); USES (Uses)
(Ag halide photog. material for color filter containing red or magenta coupler)

RN 223734-73-4 CAPLUS
CN Glycine, N-[[5-(acetylamino)-4-[[2-chloro-4-(hexadecyloxy)phenyl]azo]-1-hydroxy-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:771963 CAPLUS
DOCUMENT NUMBER: 130:135821
TITLE: Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics
AUTHOR(S): Groves, Matthew R.; Yao, Zhu-Jun; Roller, Peter P.; Burke, Terrence R., Jr.; Barford, David
CORPORATE SOURCE: Laboratory of Molecular Biophysics Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK
SOURCE: Biochemistry (1998), 37(51), 17773-17783
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Protein tyrosine phosphatases regulate diverse cellular processes and represent important targets for therapeutic intervention in a number of diseases. The crystal structures of protein tyrosine phosphatase 1B (PTP1B) in complex with small mol. inhibitors based upon two classes of phosphotyrosine mimetics, the (difluoronaphthylmethyl)phosphonic acids and the fluoromalonyl tyrosines, have been determined to resolns. greater than 2.3 Å. The fluoromalonyl tyrosine residue was incorporated within a cyclic hexapeptide modeled on an autophosphorylation site of the epidermal growth factor receptor. The structure of this inhibitor bound to PTP1B represents the first crystal structure of a non-phosphonate-containing inhibitor and reveals the mechanism of phosphotyrosine mimicry by the fluoromalonyl tyrosine residue and the nature of its interactions within the catalytic site of PTP1B. In contrast to complexes of PTP1B with phosphotyrosine-containing peptides, binding of the fluoromalonyl tyrosine residue to the catalytic site of PTP1B is not accompanied by closure of the catalytic site WPD loop. Structures of PTP1B in complex with the (difluoronaphthylmethyl)phosphonic acid derivs. reveal that substitutions of the naphthalene ring modulate the mode of inhibitor binding to the catalytic site and provide the potential for enhanced inhibitor affinity and the generation of PTP-specific inhibitors. These results provide a framework for the rational design of higher affinity and more specific phosphotyrosine mimetic inhibitors of not only protein tyrosine phosphatases but also SH2 and PTB domains.

IT 219316-41-3
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(structural basis for inhibition of protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics)

RN 219316-41-3 CAPLUS

CN Pentanoic acid, 5-amino-4-[[[7-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:737268 CAPLUS

DOCUMENT NUMBER: 130:95825

TITLE: Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors

AUTHOR(S): Yao, Zhu-Jun; Ye, Bin; Wu, Xiong-Wu; Wang, Shaomeng; Wu, Li; Zhang, Zhong-Yin; Burke, Terrence R., Jr.

CORPORATE SOURCE: Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(10), 1799-1810
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II



III

AB Protein-tyrosine phosphatase (PTP) inhibitors are attractive as potential

signal transduction-directed therapeutics which may be useful in the treatment of a variety of diseases. New naphthyldifluoromethyl phosphonic acids I and II were designed bearing acidic functionality intended to interact with the protein-tyrosine phosphatase 1B (PTP1B) Arg47, which is situated just outside the catalytic pocket. This residue has been shown previously to provide key interactions with acidic residues of phosphotyrosyl-containing peptide substrates. Consistent with trends predicted by mol. dynamics calcns., the new analogs bound with 7- to 14-fold higher affinity than the parent III, in principal validating the design rationale.

IT 219316-40-2P 219316-41-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of glutamate-substituted naphthyldifluoromethylphsophonic acids as protein-tyrosine phosphatase 1B inhibitors)

RN 219316-40-2 CAPLUS
CN Pentanoic acid, 5-amino-4-[[[6-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219316-41-3 CAPLUS
CN Pentanoic acid, 5-amino-4-[[[7-(difluorophosphonomethyl)-2-naphthalenyl]carbonyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:689253 CAPLUS
DOCUMENT NUMBER: 129:283377
TITLE: Color photographic material with non-diffusive 2-equivalent coupler
INVENTOR(S): Bell, Peter; Borst, Hans-Ulrich; Buescher, Ralf; Siegel, Joerg
PATENT ASSIGNEE(S): Agfa Gevaert A.-G., Germany
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX

10/517,677

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 19712692 | A1 | 19981001 | DE 1997-19712692 | 19970326 |
| US 6083675 | A | 20000704 | US 1998-44782 | 19980319 |

PRIORITY APPLN. INFO.: DE 1997-19712692 A 19970326

AB In the title material comprising at least 1 cyan coupler-containing, red-sensitive Ag halide emulsion layer, at least 1 magenta coupler-containing, green-sensitive Ag halide emulsion layer, at least 1 yellow coupler-containing, Ag halide emulsion layer, and optionally further light-insensitive layers, at least 1 of the Ag halide emulsion layers contains a non-diffusive 2-equiv color coupler. The material shows improved sensitivity/graininess or gradation/graininess relation.

IT 213980-41-7
RL: MOA (Modifier or additive use); USES (Uses)
(color photog. material with non-diffusive 2-equiv coupler)

RN 213980-41-7 CAPLUS

CN Glycine, N-[[4-[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]ethoxy]-1-hydroxy-5-[[(2-methylpropoxy)carbonyl]amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:677821 CAPLUS
DOCUMENT NUMBER: 129:302890
TITLE: Treatment of cancer using a combination of integrin antagonists and farnesyl protein transferase inhibitors.
INVENTOR(S): Duggan, Mark E.; Hartman, George D.; Heimbrook, David C.; Oliff, Allen I.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 422 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9844797 | A1 | 19981015 | WO 1998-US6823 | 19980406 |
| W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2286239 | A1 | 19981015 | CA 1998-2286239 | 19980406 |
| AU 9869532 | A | 19981030 | AU 1998-69532 | 19980406 |
| AU 724216 | B2 | 20000914 | | |
| EP 973396 | A1 | 20000126 | EP 1998-915318 | 19980406 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001524079 | T | 20011127 | JP 1998-543013 | 19980406 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 1997-41923P | P | 19970407 |
| | GB 1998-976 | A | 19980116 |
| | WO 1998-US6823 | W | 19980406 |

OTHER SOURCE(S): MARPAT 129:302890

AB A method of achieving a therapeutic effect comprising administration of an integrin antagonist and a farnesyl-protein transferase inhibitor where the amount of either alone is insufficient to achieve the effect, is claimed (no data). Amino acid and peptide derivs., e.g., N-[(2R)-amino-3-mercaptopropyl]valylisoleucylleucine, were prepared

IT 206997-13-9 206997-24-2 206997-25-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of cancer using a combination of integrin antagonists and farnesyl protein transferase inhibitors)

RN 206997-13-9 CAPLUS
CN L-Alanine, N-(phenylsulfonyl)-3-[[[6-[(2-pyridinylamino)methyl]-2-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206997-24-2 CAPLUS
CN L-Alanine, N-(phenylsulfonyl)-3-[[[6-[(2-pyrimidinylamino)methyl]-2-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206997-25-3 CAPLUS
CN L-Alanine, N-(phenylsulfonyl)-3-[[[6-[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]methyl]-2-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:668012 CAPLUS
DOCUMENT NUMBER: 129:290438
TITLE: Preparation of CS-1 peptidomimetics and their compositions
INVENTOR(S): Arrhenius, Thomas S.; Elices, Mariano J.; Gaeta, Federico C. A.
PATENT ASSIGNEE(S): Cytel Corp., USA
SOURCE: U.S., 81 pp., Cont.-in-part of U.S. Ser. No. 349,024. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5821231 | A | 19981013 | US 1995-461056 | 19950605 |
| CA 2177840 | A1 | 19950615 | CA 1994-2177840 | 19941205 |
| CN 1142832 | A | 19970212 | CN 1994-194969 | 19941205 |
| US 5688913 | A | 19971118 | US 1995-435286 | 19950505 |
| US 6117840 | A | 20000912 | US 1997-837154 | 19970414 |
| US 6103870 | A | 20000815 | US 1997-923026 | 19970903 |
| PRIORITY APPLN. INFO.: | | | US 1993-164101 | B2 19931206 |
| | | | US 1994-349024 | A2 19941202 |
| | | | US 1995-435286 | A1 19950505 |

OTHER SOURCE(S): MARPAT 129:290438
GI



I

AB Peptidomimetics I (R1 = alkyl, aminoalkyl, or a ring structure which may form at R1, between R1 and R2 or between R1 and R4; R2 = H, Me or R2 and R1 form the R1 ring structure group; R3 = alkyl, alkyl alc., thioalkyl or a ring structure; R4 = H or R4 and R1 form the R1 ring structure; R5 = H or R5 and R6 form a ring structure; R6 = benzyl, 1,1-diphenylmethine, or the R5 ring structure) were prepared as inhibitors of the binding between the VLA-4 receptor and the fibronectin CS-1 domain. Thus, N-phenylacetyl-Leu-Asp-Phe-D-Pro-NH2 was prepared and assayed for binding inhibition potency (313 relative to a standard compound).

IT 209602-54-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of CS-1 peptidomimetics and their compns.)

RN 209602-54-0 CAPLUS

CN D-Prolinamide, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-L-α-aspartyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:427769 CAPLUS
DOCUMENT NUMBER: 129:95722
TITLE: Preparation of CS-1 peptidomimetics and their compositions
INVENTOR(S): Arrhenius, Thomas S.; Elices, Mariano J.; Gaeta, Federico C. A.
PATENT ASSIGNEE(S): Cytel Corp., USA
SOURCE: U.S., 80 pp., Cont.-in-part of U.S. Ser. No. 349,024.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5770573 | A | 19980623 | US 1995-462219 | 19950605 |
| CA 2177840 | A1 | 19950615 | CA 1994-2177840 | 19941205 |

| | | | | | |
|---|---|---|---|---|---|
| CN 1142832 | A | 19970212 | CN 1994-194969 | | 19941205 |
| US 5688913 | A | 19971118 | US 1995-435286 | | 19950505 |
| US 6117840 | A | 20000912 | US 1997-837154 | | 19970414 |
| US 6103870 | A | 20000815 | US 1997-923026 | | 19970903 |
| PRIORITY APPLN. INFO.: | | | US 1993-164101 | B2 | 19931206 |
| | | | US 1994-349024 | A2 | 19941202 |
| | | | US 1995-435286 | A1 | 19950505 |

OTHER SOURCE(S): MARPAT 129:95722
GI



I

AB Peptidomimetics I (R1 = alkyl, aminoalkyl, or a ring structure which may form at R1, between R1 and R2 or between R1 and R4; R2 = H, Me or R2 and R1 form the R1 ring structure group; R3 = alkyl, alkyl alc., thioalkyl or a ring structure; R4 = H or R4 and R1 form the R1 ring structure; R5 = H or R5 and R6 form a ring structure; R6 = benzyl, 1,1-diphenylmethine, or the R5 ring structure) were prepared as inhibitors of the binding between the VLA-4 receptor and the fibronectin CS-1 domain. Thus, N-phenylacetyl-Leu-Asp-Phe-D-Pro-NH2 was prepared and assayed for binding inhibition potency (313 relative to a standard compound).

IT 209602-54-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of CS-1 peptidomimetics and their compns.)

RN 209602-54-0 CAPLUS

CN D-Prolinamide, N-[(3,7-dihydroxy-2-naphthalenyl)carbonyl]-L-α-aspartyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

| | |
|---|---|
| ACCESSION NUMBER: | 1998:293369 CAPLUS |
| DOCUMENT NUMBER: | 128:321934 |
| TITLE: | Preparation of amino acid derivatives as integrin antagonists |
| INVENTOR(S): | Duggan, Mark E.; Hartman, George D.; Hoffman, William F.; Ihle, Nathan C. |
| PATENT ASSIGNEE(S): | Merck & Co., Inc., USA; Duggan, Mark E.; Hartman, George D.; Hoffman, William F.; Ihle, Nathan C. |
| SOURCE: | PCT Int. Appl., 98 pp. |

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9818461 | A1 | 19980507 | WO 1997-US19349 | 19971027 |
| W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2268916 | A1 | 19980507 | CA 1997-2268916 | 19971027 |
| AU 9850884 | A | 19980522 | AU 1998-50884 | 19971027 |
| AU 717283 | B2 | 20000323 | | |
| EP 946164 | A1 | 19991006 | EP 1997-913775 | 19971027 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 2001504456 | T | 20010403 | JP 1998-520639 | 19971027 |
| US 5919792 | A | 19990706 | US 1997-959662 | 19971028 |

PRIORITY APPLN. INFO.: US 1996-29223P P 19961030
GB 1996-26308 A 19961218
WO 1997-US19349 W 19971027

OTHER SOURCE(S): MARPAT 128:321934

AB Amino acids derivs. X-Y-Z-Ring-A-B [Ring is a mono- or polycyclic ring system; X = NR1R2, NR1CR3:NR2, C(:NR2)NHR4, NR1C(:NR2)NR3R4, aryl-NR1R2, aryl-C(:NR1)NR2R3, aryl-NR1C(:NR2)NR3R4, (R1-R4 = H, halo, alkyl, arylalkyl, aminoalkyl, etc.), a mono- or polycyclic ring system; Y = alkylene, imino-, carbonyl-, oxydialkylene, etc.; Z = (CH2)m, (CH2)mO(CH2)n, (CH2)mC.tplbond.C(CH2)n, etc. (m, n = 0-6); A = (CH2)qO(CH2)p, (CH2)qCS(CH2)p (p, q = 0-6), etc.; B = (un)substituted carboxy- or carbamoylalkyl, including amino acid residues] were prepared as vitronectin receptor antagonists. Thus, 4-[2-(2-aminopyridin-6-yl)ethyl]benzoyl-2(S)-[[(4-125iodophenyl)sulfonyl]amino]-β-alanine was prepared and used in a formulation for inhibition of bone resorption.

IT 206997-24-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. as integrin antagonists)

RN 206997-24-2 CAPLUS

CN L-Alanine, N-(phenylsulfonyl)-3-[[[6-[(2-pyrimidinylamino)methyl]-2-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 206997-13-9P 206997-14-0P 206997-25-3P

NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:480308 CAPLUS
DOCUMENT NUMBER: 127:101700
TITLE: Silver halide color photographic material containing pyvaloylacetanilide yellow coupler and oxidized developer scavenger
INVENTOR(S): Ishii, Yoshio; Kobayashi, Hidetoshi; Obayashi, Keiji
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 68 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 09146237 | A | 19970606 | JP 1995-322430 | 19951117 |

PRIORITY APPLN. INFO.: JP 1995-322430 19951117
GI



I

AB Claimed photog. color material having ≥1 light-sensitive Ag halide emulsion layer and ≥1 light-insensitive layer contains a coupler I (R1 = tert-alkyl; R2 = halo, alkoxy, aryloxy, alkyl, alkylsulfonyloxy, cycloalkyl; R3 = alkoxycarbonyloxy, alkylsulfonyloxy; R4 = halo, alkyl, heterocyclic group; n = 0, 1, 2; R5, R6 = H, alkyl; X = O, S, imino) and a compound having the structure (coup)-(time)-(s.c.) (II), where coup is a coupler moiety, time is a timing group to control the releasing rate and s.c. is scavenger of oxidized developing material. It has high speed and low fog. It also improves storage stability, and suitably applied to a multilayer color neg. material. Suitable couplers are coupler I (R1 =

tert-butyl; R2 = Cl; R3 = n-tetradecyloxycarbonyl; n = 0; R5, R6 = Me; X = NCH3), coupler I (R1 = tert-butyl; R2 = Cl; R3 = n-tetradecyloxycarbonyl; n = 0; R5, R6 = Me; X = O), etc., and suitable compound II is 2-carboxyethylcarbamino-4-dodecyloxyethylcarbamoylmethoxy-naphthol.

IT 189264-50-4
RL: DEV (Device component use); USES (Uses)
(oxidized developer scavenger; color photog. material containing pyvaloylacetanilide yellow coupler to improve storage stability)

RN 189264-50-4 CAPLUS

CN β-Alanine, N-[[5-[[(carboxymethoxy)carbonyl]amino]-1-hydroxy-4-[4-hydroxy-2,5-bis(1,1,3,3-tetramethylbutyl)phenoxy]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:334667 CAPLUS
DOCUMENT NUMBER: 126:310419
TITLE: Full color silver halide photographic material containing hydroxylamines or hydroxamic acids
INVENTOR(S): Obayashi, Keiji; Ishii, Yoshio
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 93 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 09068784 | A | 19970311 | JP 1995-245199 | 19950831 |

PRIORITY APPLN. INFO.: JP 1995-245199 19950831

AB The title photog. material contains a compound selected from R1R2NOH, X(R3)NOH and (R1 = alkyl, alkenyl, aryl, acyl, alkyl- or aryl-substituted sulfonyl or sulfinyl, carbamoyl, sulfamoyl, alkoxycarbonyl, aryloxycarbonyl; R2 = H or group defined for R1; R1 and R2 may joint to form a 5-7-membered ring except s-triazine; X = heterocyclic ring except s-triazine; R3 = alkyl, alkenyl, aryl; x and R3 may joint to form a 5-7-membered ring except s-triazine; Y = non-metallic atoms required to form 5-6-membered ring except s-triazine) and a compound or its precursor capable of scavenging the oxidized developer. The invention photog. material can prevent color from mixing.

IT 189264-50-4
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)

(oxidized developer scavenger contained in photog. material for preventing color mixing)

RN 189264-50-4 CAPLUS

CN β-Alanine, N-[[5-[[(carboxymethoxy)carbonyl]amino]-1-hydroxy-4-[4-hydroxy-2,5-bis(1,1,3,3-tetramethylbutyl)phenoxy]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:72137 CAPLUS

DOCUMENT NUMBER: 116:72137

TITLE: Silver halide positive color photographic materials, and their processing

INVENTOR(S): Sakagami, Megumi; Ichijima, Yasushi

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 03096945 | A | 19910422 | JP 1989-235077 | 19890911 |

PRIORITY APPLN. INFO.: JP 1989-235077 19890911

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title materials contain compds. CpN:NR(ballast) or compds. (DyeCp)X(ballast) [Cp = coupling group; Cp and (DyeCp) groups have alkali dissociation groups that may be in salt form; Dye = dye residue; R = divalent group with ≥1 unsatd. group that conjugates with N:N; X = leaving group; (ballast) = ballast group; -N:NR(ballast) group is bonded to coupling position of Cp]. Exposed materials are processed by color development and desilvering. These materials provide color pos. image without reversal process by simple procedure. Thus, in a 9-layer color photog. film, the 3rd layer was a red-sensitive emulsion layer containing compound I, the 5th layer was a green-sensitive emulsion layer containing compound II, and the 7th was a blue-sensitive emulsion layer containing compound III.

Imagewise exposed film was processed by color development, bleaching, and bleach-fixing and gave pos. image with min. d. ≤0.2 for each color.

IT 137052-11-0
RL: USES (Uses)
(coupler, for pos. color film without reversal process)

RN 137052-11-0 CAPLUS

CN β-Alanine, N-[[4-[[4-(didodecylamino)phenyl]azo]-5-[(ethoxycarbonyl)amino]-1-hydroxy-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:619508 CAPLUS
DOCUMENT NUMBER: 109:219508
TITLE: Silver halide color photographic photosensitive materials containing novel couplers
INVENTOR(S): Ninomiya, Hidetaka; Kimura, Toshihiko; Masukawa, Toyoaki; Tsuda, Yasuo; Nakayama, Noritaka
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 63110451 | A | 19880514 | JP 1986-257995 | 19861029 |

PRIORITY APPLN. INFO.: JP 1986-257995 19861029

GI



I

AB The title color photog. materials contain couplers of the formula I (Z = naphthol or phenol derivative type coupler moiety; R = hydrophilic group; R1, R2 = alkyl, alkenyl, aryl, heterocyclyl; R3 = substituent; n = 0, 1, 2; Z and R are selected that the dye formed by reaction of the coupler moiety with oxidized developing agent will not remain in the photosensitive material after the processing). The coupler releases a reducing agent upon coupling reaction to scavenge the oxidized color developing agent.

IT 117568-94-2
RL: USES (Uses)
(oxidized developer scavenger-releasing photog. coupler)

RN 117568-94-2 CAPLUS

CN β-Alanine, N-[[4-[2,4-bis[[(1,1,3,3-tetramethylbutyl)sulfonyl]amino]phenoxy]-1-hydroxy-5-[[(2-methylpropoxy)carbonyl]amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:493611 CAPLUS

DOCUMENT NUMBER: 109:93611

TITLE: Preparation and testing of (aminopropoxy)naphthylcarboxamidopentylalanylprolines and indole analogs as cardiovascular agents

INVENTOR(S): Allan, Geoffrey; Hardy, George William; Bull, Donald; Mills, Gail; Lee, Grahame Roy

PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK

SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 234946 | A2 | 19870902 | EP 1987-301740 | 19870227 |
| EP 234946 | A3 | 19880817 | | |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| DK 8701033 | A | 19870829 | DK 1987-1033 | 19870227 |
| FI 8700872 | A | 19870829 | FI 1987-872 | 19870227 |
| AU 8769536 | A | 19870903 | AU 1987-69536 | 19870227 |
| JP 62252799 | A | 19871104 | JP 1987-45119 | 19870227 |

| | | | | | |
|---|---|---|---|---|---|
| HU 46045 | A2 | 19880928 | HU 1987-816 | | 19870227 |
| ZA 8701454 | A | 19881026 | ZA 1987-1454 | | 19870227 |
| DD 263052 | A5 | 19881221 | DD 1987-300269 | | 19870227 |
| PRIORITY APPLN. INFO.: | | | GB 1986-5049 | A | 19860228 |
| | | | GB 1986-20767 | A | 19860828 |

OTHER SOURCE(S): MARPAT 109:93611

AB Me2CHNHCH2CH(OH)CH2OXCONH(CH2)4CHZNHCHMeCOY (I; X = naphthyl, indolyl ring system; Y = CO2H, C2-5 alkoxycarbonyl; Z = carboxypyrrolidinyl) were prepared as antihypertensives. Me 4-hydroxyindole-2-carboxylate (preparation given) was treated with NaH in DMF and 2S-glycidyl tosylate was added at 0°. The mixture was stirred 3 h at 50° to give the 4-oxiranylmethoxy compound, which was heated with Me2CHNH2 in DMF/H2O to give Me 4-[2(S)-hydroxy-3-isopropylamino]-1H-indole-2-carboxylate. The latter was N-protected, saponified, coupled with tert-Bu N-[1(S)-tert-butoxycarbonyl-5-aminopentyl]-(S)alanyl-(S)-prolinate (preparation given) to give N-1S-carboxy-5-[4-(2S-hydroxy-3-isopropylaminopropoxy)-1H-indol-2-ylcarboxamido]pentyl-S-alanyl-S-proline. The latter inhibited ACE in a test of angiotensin-I-induced pig ileum contractility with an EC50 of 1.4 nM.

IT 115724-72-6P 115724-73-7P 115724-74-8P
115724-75-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as cardiovascular agent)

RN 115724-72-6 CAPLUS

CN L-Proline, 1-[N-[1-carboxy-5-[[[5-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2-naphthalenyl]carbonyl]amino]pentyl]alanyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 115724-73-7 CAPLUS

CN L-Proline, 1-[N-[1-carboxy-5-[[[8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2-naphthalenyl]carbonyl]amino]pentyl]alanyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 115724-74-8 CAPLUS

CN L-Proline, 1-[N-[1-carboxy-5-[[[5-[2-hydroxy-3-[(1-



L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:617258 CAPLUS
DOCUMENT NUMBER: 107:217258
TITLE: Bicyclic naphthalenic derivatives, a process for their preparation and their use in pharmaceuticals and cosmetics
INVENTOR(S): Maignan, Jean; Lang, Gerard; Malle, Gerard; Restle, Serge; Shroot, Braham
PATENT ASSIGNEE(S): Centre International de Recherches Dermatologiques (CIRD), Fr.
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 220118 | A2 | 19870429 | EP 1986-402257 | 19861010 |
| EP 220118 | A3 | 19881109 | | |
| EP 220118 | B1 | 19920102 | | |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE | | | | |
| FR 2590566 | A1 | 19870529 | FR 1985-15106 | 19851011 |
| FR 2590566 | B1 | 19871231 | | |
| FR 2601359 | A1 | 19880115 | FR 1986-10020 | 19860709 |
| FR 2601359 | B1 | 19881028 | | |
| ZA 8607705 | A | 19870624 | ZA 1986-7705 | 19861009 |
| DK 8604848 | A | 19870412 | DK 1986-4848 | 19861010 |
| DK 171347 | B1 | 19960916 | | |
| FI 8604106 | A | 19870412 | FI 1986-4106 | 19861010 |
| FI 87455 | B | 19920930 | | |
| FI 87455 | C | 19930111 | | |
| NO 8604040 | A | 19870413 | NO 1986-4040 | 19861010 |
| NO 164971 | B | 19900827 | | |
| NO 164971 | C | 19910611 | | |
| AU 8663859 | A | 19870416 | AU 1986-63859 | 19861010 |
| AU 588385 | B2 | 19890914 | | |
| CA 1267420 | A1 | 19900403 | CA 1986-520279 | 19861010 |
| CA 1270766 | A1 | 19900626 | CA 1986-520278 | 19861010 |
| AT 71080 | T | 19920115 | AT 1986-402257 | 19861010 |
| ES 2003065 | T3 | 19930801 | ES 1986-402257 | 19861010 |
| JP 62135441 | A | 19870618 | JP 1986-240222 | 19861011 |
| US 4826969 | A | 19890502 | US 1986-918507 | 19861014 |
| NO 8904197 | A | 19870413 | NO 1989-4197 | 19891020 |
| NO 166483 | B | 19910422 | | |
| NO 166483 | C | 19910731 | | |
| FI 90528 | B | 19931115 | FI 1991-4628 | 19911002 |
| FI 90528 | C | 19940225 | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| FR 1985-15106 | A | 19851011 |
| FR 1986-10020 | A | 19860709 |
| EP 1986-402257 | A | 19861010 |
| NO 1986-4040 | A1 | 19861010 |

OTHER SOURCE(S): CASREACT 107:217258; MARPAT 107:217258
GI




I




II




III

AB Title compds. I [A = (alkyl-substituted) CH2, CH2CH2; R1-R4 = H, C1-6 alkyl; R1R3 = CH2, CH2CH2; R5 = H, OH, alkoxy, amino; R6 = H, alkyl; R5R6 = O, CH2, NHOH; R = CH2OH, CHO, acyl, amido] are prepared and formulated into pharmaceuticals for treatment of dematol., respiratory, or ophthalmol. conditions, and cosmetics for body and hair hygiene. Indane II (A = CH2, R1-R4 = Me) was acylated by naphthalenoyl chloride III (R6 = Me) to give I (R5R6 = O; R = CO2Me), which was saponified to form I (R = CO2H) (IV). Tablets were formed from IV 0.005, amidon 0.110, bicalcium phosphate 0.020, silica 0.020, lactose 0.030, talc 0.010, and Mg stearate 0.005 g.

IT 110952-33-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as dermatol. pharmaceutical and cosmetic)

RN 110952-33-5 CAPLUS

CN L-Methionine, N-[[6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1983:16101 CAPLUS
DOCUMENT NUMBER: 98:16101
TITLE: Hydrolysis of N,N'-disubstituted diimides of 1,4,5,8-naphthalenetetracarboxylic acid. I. Structure of hydrolysis products and equilibrium position in relation to the pH of the medium
AUTHOR(S): Kheifets, G. M.; Martyushina, N. V.
CORPORATE SOURCE: Inst. Eksp. Med., Leningrad, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1982), 18(8), 1750-9

CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I



II

AB N,N'-Bis(arylimides) of the title acid, e.g., I are hydrolyzed at pH 6-8 and 37° with opening of 1 imide ring; the 2nd imide ring is opened at pH >9. N,N'-Bis(alkylimides), e.g., II [R = (CH2)3N+Me3, (CH2)3SO3-, (CH2)5CO2-], open only 1 ring at pH >9; the resulting amides are not hydrolyzed at pH 6-11 and 37°, and the process is reversible. At pH 0-3 the hydrolysis of the diimides proceeds slowly and irreversibly to give the monoimides. The intermediacy of imide anhydrides is discussed.

IT 83858-26-8P
RL: PRP (Properties); FORM (Formation, nonpreparative); PREP (Preparation) (formation and electronic spectrum of)

RN 83858-26-8 CAPLUS

CN 1,5-Naphthalenedicarboxylic acid, 4,8-bis[[(3-carboxypropyl)amino]carbonyl]-, ion(4-) (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1981:39527 CAPLUS
DOCUMENT NUMBER: 94:39527
TITLE: Purification of photographic image-forming sulfonamido compounds employing immiscible solvents
INVENTOR(S): Milner, Nigel E.; Payne, Christine C.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 4228070 | A | 19801014 | US 1979-15972 | 19790228 |
| CA 1117523 | A1 | 19820202 | CA 1979-322808 | 19790306 |
| PRIORITY APPLN. INFO.: | | | US 1979-15972 A | 19790228 |

AB The purification of sulfonamido image forming compds. (alkali-clearable upon oxidation to release a diffusible sulfonamido color forming moiety) which are useful in diffusion transfer photog., involves dissoln. in DMF, extraction of impurities with petroleum hydrocarbon, and recovery of the compound from DMF solution Thus, the crude 3-chloro-2-hydroxy-5-{4-[4-hydroxy-3-(N,N-dioctadecylcarbamoyl)-1-naphthylsulfamoyl]phenylazo}benzamide (I) 50 g was dissolved in DMF 500, extracted with ligroin (b.p. 60-80°) (2 + 500 mL), mixed with EtOAc 900 mL, extracted with H2O 3 L, and the separated EtOAc evaporated to give an oil which was crystallized from MeOH/MeEtCO mixture to give 40 g of the purified I.

IT 73241-00-6 73681-64-8
RL: USES (Uses)
(purification method for)

RN 73241-00-6 CAPLUS
CN Glycine, N-[[4-[[3-[[[3-[(dioctadecylamino)carbonyl]-4-hydroxy-1-naphthalenyl]amino]sulfonyl]phenyl]azo]-1-hydroxy-5-[(methylsulfonyl)amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 73681-64-8 CAPLUS
CN Glycine, N-[[1-hydroxy-4-[[3-[[[4-hydroxy-3-[[[2-(3-pentadecylphenoxy)butyl]amino]carbonyl]-1-naphthalenyl]amino]sulfonyl]phenyl]azo]-5-[(methylsulfonyl)amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:207037 CAPLUS
DOCUMENT NUMBER: 92:207037
TITLE: Magenta dyes and redox dye releasers
AUTHOR(S): Bogie, J. A.; Cox, I. R.; Kilminster, K. N.
CORPORATE SOURCE: Kodak Ltd., UK
SOURCE: Research Disclosure (1980), 189, 4-7 (No. 18902)
CODEN: RSDSBB; ISSN: 0374-4353
DOCUMENT TYPE: Journal; Patent
LANGUAGE: English
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| RD 189002 | | 19800110 | | |
| PRIORITY APPLN. INFO.: | | | RD 1980-189002 | 19800110 |

GI



AB Redox dye-releasers having the formula I (R = a carrier group capable of releasing image dye under alkaline conditions as a function of Ag halide development; R1 = H, SO2NH, CO2H; R2 = H, alkyl; R3 = alkyl, aryl, substituted alkyl or aryl, or together with R2 completes a heterocycle; R4 = alkyl-, aryl-, or substituted arylcarbonyl or -sulfonyl) are described. These compds. have an especially desirable light and heat stability, diffusion



RN 73681-64-8 CAPLUS
CN Glycine, N-[[1-hydroxy-4-[[3-[[[4-hydroxy-3-[[[2-(3-pentadecylphenoxy)butyl]amino]carbonyl]-1-naphthalenyl]amino]sulfonyl]phenyl]azo]-5-[(methylsulfonyl)amino]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:28:58 ON 01 FEB 2007)

FILE 'REGISTRY' ENTERED AT 15:29:26 ON 01 FEB 2007
L1 STRUCTURE UPLOADED
L2 3 S L1

10/517,677

L3 67 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:30:00 ON 01 FEB 2007
L4 35 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

=>